QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
revised:
08
09
2020
received:
16
06
2020
accepted:
04
10
2020
pubmed:
17
10
2020
medline:
12
5
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
The liberal administration of hydroxychloroquine-sulphate (HCQ) to COVID-19 patients has raised concern regarding the risk of QTc prolongation and cardiac arrhythmias, particularly when prescribed with azithromycin. We evaluated the incidence of QTc prolongation among moderately and severely ill COVID-19 patients treated with HCQ and of the existence of concomitant alternative causes. All COVID-19 patients treated with HCQ (between Mar 1 and Apr 14, 2020) in a tertiary medical centre were included. Clinical characteristics and relevant risk factors were collected from the electronic medical records. Individual patient QTc intervals were determined before and after treatment with HCQ. The primary outcome measure sought was a composite end point comprised of either an increase ≥60 milliseconds (ms) in the QTc interval compared with pre-treatment QTc, and/or a maximal QTc interval >500 ms RESULTS: Ninety patients were included. Median age was 65 years (IQR 55-75) and 57 (63%) were male. Thirty-nine patients (43%) were severely or critically ill. Hypertension and obesity were common (n = 23 each, 26%). QTc prolongation evolved in 14 patients (16%). Age >65 years, congestive heart failure, severity of disease, C-reactive protein level, hypokalaemia and furosemide treatment, were all associated with QTc prolongation. Adjusted analysis showed that QTc prolongation was five times more likely with hypokalaemia [OR 5, (95% CI, 1.3-20)], and three times more likely with furosemide treatment [OR 3 (95% CI, 1.01-13.7)]. In patients treated with HCQ, QTc prolongation was associated with the presence of traditional risk factors such as hypokalaemia and furosemide treatment.
Sections du résumé
BACKGROUND
BACKGROUND
The liberal administration of hydroxychloroquine-sulphate (HCQ) to COVID-19 patients has raised concern regarding the risk of QTc prolongation and cardiac arrhythmias, particularly when prescribed with azithromycin. We evaluated the incidence of QTc prolongation among moderately and severely ill COVID-19 patients treated with HCQ and of the existence of concomitant alternative causes.
METHODS
METHODS
All COVID-19 patients treated with HCQ (between Mar 1 and Apr 14, 2020) in a tertiary medical centre were included. Clinical characteristics and relevant risk factors were collected from the electronic medical records. Individual patient QTc intervals were determined before and after treatment with HCQ. The primary outcome measure sought was a composite end point comprised of either an increase ≥60 milliseconds (ms) in the QTc interval compared with pre-treatment QTc, and/or a maximal QTc interval >500 ms RESULTS: Ninety patients were included. Median age was 65 years (IQR 55-75) and 57 (63%) were male. Thirty-nine patients (43%) were severely or critically ill. Hypertension and obesity were common (n = 23 each, 26%). QTc prolongation evolved in 14 patients (16%). Age >65 years, congestive heart failure, severity of disease, C-reactive protein level, hypokalaemia and furosemide treatment, were all associated with QTc prolongation. Adjusted analysis showed that QTc prolongation was five times more likely with hypokalaemia [OR 5, (95% CI, 1.3-20)], and three times more likely with furosemide treatment [OR 3 (95% CI, 1.01-13.7)].
CONCLUSION
CONCLUSIONS
In patients treated with HCQ, QTc prolongation was associated with the presence of traditional risk factors such as hypokalaemia and furosemide treatment.
Identifiants
pubmed: 33063447
doi: 10.1111/ijcp.13767
pmc: PMC7646017
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13767Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Int J Clin Pract. 2021 Mar;75(3):e13767
pubmed: 33063447
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87
pubmed: 23716032
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
J Rheumatol. 2015 Mar;42(3):421-8
pubmed: 25593223
Front Cardiovasc Med. 2015 May 27;2:26
pubmed: 26798623
Crit Care. 2020 Apr 28;24(1):176
pubmed: 32345343
Circulation. 2018 Nov 20;138(21):2345-2358
pubmed: 30571576
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1663-1672
pubmed: 32278065
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041
pubmed: 32936252
J Am Coll Cardiol. 2020 May 26;75(20):2623-2624
pubmed: 32283123
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
JAMA Netw Open. 2020 Jun 1;3(6):e2011122
pubmed: 32525548
Eur J Clin Pharmacol. 2018 Feb;74(2):183-191
pubmed: 29167918
Circulation. 2010 Mar 2;121(8):1047-60
pubmed: 20142454
PLoS One. 2018 Jun 13;13(6):e0199028
pubmed: 29898002
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
Nat Med. 2020 Jun;26(6):808-809
pubmed: 32488217